Relationship between encapsulated drug particle size and initial release of recombinant human growth hormone from biodegradable microspheres

Costantino, Henry R.; Johnson, OluFunmi L.; Zale, Stephen E.

doi:10.1002/jps.20078

Cited by 32 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though the PLGA microspheres obtained seemed with 12±4 μm to be somewhat smaller for encapsulated HRP nanoparticles compared with those obtained with lyophilized HRP powder (20±11 μm), there was no statistical significance (p<0.1). Given that the microsphere size was not very different, drug particle size should be of major importance (17). Larger drug particles will statistically be closer to the surface of the microspheres and therefore release should be faster.…”

Section: Resultsmentioning

confidence: 99%

Improved Enzyme Activity and Stability in Polymer Microspheres by Encapsulation of Protein Nanospheres

2012

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Improved Enzyme Activity and Stability in Polymer Microspheres by Encapsulation of Protein Nanospheres

2012

View full text Add to dashboard Cite

“…For instance, protein drugs can be encapsulated into biodegradable polymers for formulating sustained or controlled release microspheres that are less prone to an initial burst release, a common problem with this type of formulation in depot drug delivery (184,186). Liposomal formulations can also be used to produce respirable dry powders by SFD although they have been traditionally used in pulmonary delivery in the form of MDIs and liquid formulations.…”

Section: Sfd Materials Properties and Applicationsmentioning

confidence: 99%

“…The most significant operating parameter governing particle size is the mass flow ratio of atomized nitrogen to liquid feed (185). A decrease in particle size can be achieved by an increase in mass flow ratio (185,186) while the addition of excipients (e.g., trehalose, ammonium sulfate) may lead to an increase in particle size (187).…”

Section: Spray Freeze Drying (Sfd) Sfd Processmentioning

confidence: 99%

Particle Engineering for Pulmonary Drug Delivery

et al. 2007

View full text Add to dashboard Cite

With the rapidly growing popularity and sophistication of inhalation therapy, there is an increasing demand for tailor-made inhalable drug particles capable of affording the most efficient delivery to the lungs and the most optimal therapeutic outcomes. To cope with this formulation demand, a wide variety of novel particle technologies have emerged over the past decade. The present review is intended to provide a critical account of the current goals and technologies of particle engineering for the development of pulmonary drug delivery systems. These technologies cover traditional micronization and powder blending, controlled solvent crystallization, spray drying, spray freeze drying, particle formation from liquid dispersion systems, supercritical fluid processing and particle coating. The merits and limitations of these technologies are discussed with reference to their applications to specific drug and/or excipient materials. The regulatory requirements applicable to particulate inhalation products are also reviewed briefly.

show abstract

“…Previous research studies have shown that the administration of CsA to the lungs in addition to base therapy can increase the overall survival rate of lung transplant patients (Iacono et al 1997 ;Costantino et al 2004 ) . However, due to its poor solubility, previous studies have utilized nebulized CsA in propylene glycol solution for inhalation to increase its bioavailability (Burkart et al 2003 ) .…”

Section: Examplementioning

confidence: 99%

Pharmaceutical Cryogenic Technologies

Yang¹,

Owens²,

Williams

2011

Formulating Poorly Water Soluble Drugs

View full text Add to dashboard Cite

Poor bioavailability associated with poorly water-soluble compounds remains a challenging issue in drug development. Particle engineering may be used to improve the physicochemical properties of poorly water-soluble compounds, thereby enhancing the bioavailability. Cryogenic technologies, including spray freeze drying (SFD), spray freezing into liquid (SFL), and thin fi lm freezing (TFF), are "bottom-up" precipitation processes to generate amorphous nanostructured aggregates with signifi cantly enlarged surface area, higher dissolution rates, and supersaturation, via rapidly inducing nucleation followed by particle growth arrest through stabilization via polymers and solidifi cation of the solvent. This chapter provides detailed description of each cryogenic process, formulation guidelines, and characterization analyses. Finally, examples of cryogenically engineered drug compositions with improved in vitro and in vivo macroscopic performance are provided to illustrate the potential benefi ts of cryogenic technologies, especially TFF.

show abstract

Relationship between encapsulated drug particle size and initial release of recombinant human growth hormone from biodegradable microspheres

Cited by 32 publications

References 20 publications

Improved Enzyme Activity and Stability in Polymer Microspheres by Encapsulation of Protein Nanospheres

Improved Enzyme Activity and Stability in Polymer Microspheres by Encapsulation of Protein Nanospheres

Particle Engineering for Pulmonary Drug Delivery

Pharmaceutical Cryogenic Technologies

Contact Info

Product

Resources

About